Nelson Dusetti, Head of the Translational Research and Innovative Therapies Department at the Cancer Research Centre of Marseille (CRCM), shared a post on LinkedIn:
“On Saturday, March 22, at 16:20, Paris Congress Centre session C.159 at JFHODs!
We’ll be discussing how a deconvolution approach, applied to the PRODIGE24 clinical cohort, helps predict patient response to chemotherapy (mFOLFIRINOX and gemcitabine) by mapping intra-tumor heterogeneity.
We will be showcasing ‘PANCprofiler,’ a stratification algorithm designed to identify resistant pancreatic adenocarcinoma phenotypes at single cell level. This project is part of the PRODIGE24/Mosapac consortium.
We look forward to seeing you and sharing perspectives on advancing personalized medicine for pancreatic cancer!”
